We are live on ! Find out more
TYRA icon

Tyra Biosciences

46 hedge funds and large institutions have $387M invested in Tyra Biosciences in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 4546 (+1)

1.61% more ownership

Funds ownership: 85.23%86.84% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

22% less capital invested

Capital invested by funds: $494M → $387M (-$108M)

37% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 19

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
0.73%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
7
Increased
12
Reduced
19
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SO
51
STRS Ohio
Ohio
-$39K -2,800 Closed
Northwestern Mutual Wealth Management
52
Northwestern Mutual Wealth Management
Wisconsin
-$4K -300 Closed

TYRA Hedge Fund Activity: Q1 2022 in Review

46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q1 2022, worth a combined $387M — down 22% from $494M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TYRA positions and 6 closed out — a net gain of 1 holder — while 12 added to existing stakes and 19 trimmed.

The largest buyer was Fairmount Funds Management, adding an estimated $7.59M. The largest seller was Frazier Management, exiting entirely with an estimated $17.6M sold.

  • 46 institutional investors held Tyra Biosciences (TYRA) as of Q1 2022, up from 45 in Q4 2021.
  • Funds reported $387M of Tyra Biosciences stock for Q1 2022, down 22% quarter-over-quarter.
  • 7 funds opened new Tyra Biosciences positions in Q1 2022 and 6 closed out, a net change of +1 holder.
  • The largest Tyra Biosciences buyer in Q1 2022 was Fairmount Funds Management, an estimated $7.59M added.
  • The largest Tyra Biosciences seller in Q1 2022 was Frazier Management, an estimated $17.6M sold.

Based on aggregated 13F filings for Q1 2022.